Scientific consensus on the COVID-19 pandemic: we need to act now

Nisreen A Alwan; Rochelle Ann Burgess; Simon Ashworth; Rupert Beale; Nahid Bhadelia; Debby Bogaert; Jennifer Dowd; Isabella Eckerle; Lynn R Goldman; Trisha Greenhalgh; Deepti Gurdasani; Adam Hamdy; William P Hanage; Emma B Hodcroft; Zoë Hyde; Paul Kellam; Michelle Kelly-Irving; Florian Krammer; Marc Lipsitch; Alan McNally; Martin McKee; Ali Nouri; Dominic Pimenta; Viola Priesemann; Harry Rutter; Joshua Silver; Devi Sridhar; Charles Swanton; Rochelle P Walensky; Gavin Yamey; Hisham Ziauddeen

doi:10.1016/S0140-6736(20)32153-X

Scientific consensus on the COVID-19 pandemic: we need to act now

Nisreen A Alwan, Rochelle Ann Burgess, Simon Ashworth, Rupert Beale, Nahid Bhadelia, Debby Bogaert, Jennifer Dowd, Isabella Eckerle, Lynn R Goldman, Trisha Greenhalgh, Deepti Gurdasani, Adam Hamdy, William P Hanage, Emma B Hodcroft, Zoë Hyde, Paul Kellam, Michelle Kelly-Irving, Florian Krammer, Marc Lipsitch, Alan McNallyMartin McKee, Ali Nouri, Dominic Pimenta, Viola Priesemann, Harry Rutter, Joshua Silver, Devi Sridhar, Charles Swanton, Rochelle P Walensky, Gavin Yamey, Hisham Ziauddeen

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	e71-e72
Journal	The Lancet
Volume	396
Issue number	10260
DOIs	https://doi.org/10.1016/S0140-6736(20)32153-X
Publication status	Published - 31 Oct 2020

Keywords

Betacoronavirus
COVID-19
Communicable Disease Control/methods
Consensus
Coronavirus Infections/prevention & control
Europe
Evidence-Based Medicine
Humans
Immunity, Herd
Pandemics/prevention & control
Pneumonia, Viral/prevention & control
SARS-CoV-2

Access to Document

10.1016/S0140-6736(20)32153-X

Cite this

Alwan, N. A., Burgess, R. A., Ashworth, S., Beale, R., Bhadelia, N., Bogaert, D., Dowd, J., Eckerle, I., Goldman, L. R., Greenhalgh, T., Gurdasani, D., Hamdy, A., Hanage, W. P., Hodcroft, E. B., Hyde, Z., Kellam, P., Kelly-Irving, M., Krammer, F., Lipsitch, M., ... Ziauddeen, H. (2020). Scientific consensus on the COVID-19 pandemic: we need to act now. The Lancet, 396(10260), e71-e72. https://doi.org/10.1016/S0140-6736(20)32153-X

@article{e83af231f0664e47805673a8ed750cbb,

title = "Scientific consensus on the COVID-19 pandemic: we need to act now",

keywords = "Betacoronavirus, COVID-19, Communicable Disease Control/methods, Consensus, Coronavirus Infections/prevention & control, Europe, Evidence-Based Medicine, Humans, Immunity, Herd, Pandemics/prevention & control, Pneumonia, Viral/prevention & control, SARS-CoV-2",

author = "Alwan, {Nisreen A} and Burgess, {Rochelle Ann} and Simon Ashworth and Rupert Beale and Nahid Bhadelia and Debby Bogaert and Jennifer Dowd and Isabella Eckerle and Goldman, {Lynn R} and Trisha Greenhalgh and Deepti Gurdasani and Adam Hamdy and Hanage, {William P} and Hodcroft, {Emma B} and Zo{\"e} Hyde and Paul Kellam and Michelle Kelly-Irving and Florian Krammer and Marc Lipsitch and Alan McNally and Martin McKee and Ali Nouri and Dominic Pimenta and Viola Priesemann and Harry Rutter and Joshua Silver and Devi Sridhar and Charles Swanton and Walensky, {Rochelle P} and Gavin Yamey and Hisham Ziauddeen",

note = "Funding Information: This work was not in any way directly or indirectly supported, funded, or sponsored by any organisation or entity. NA has experienced prolonged COVID-19 symptoms. AH advises Ligandal (unpaid advisory role), outside the submitted work. FK is collaborating with Pfizer on animal models of SARS-CoV-2, and with the University of Pennsylvania on mRNA vaccines against SARS-CoV-2. FK has also filed IP regarding serological assays and for SARS-CoV-2, which name him as inventor (pending). PK reports personal fees from Kymab, outside the submitted work; PK also has a patent {\textquoteleft}Monoclonal antibodies to treat and prevent infection by SARS-CoV-2 (Kymab){\textquoteright} pending and is a scientific advisor to the Serology Working Group (Public Heath England), Testing Advisory Group (Department of Health and Social Care) and the Vaccines Task force (Department for Business, Energy and Industrial Strategy). ML has received honoraria from Bristol-Meyers Squibb and Sanofi Pasteur, outside the submitted work. MM is a member of Independent SAGE and Research Director European Observatory on Health Systems and Policies, which manages the COVID Health Systems Response Monitor. DS sits on the Scottish Government COVID-19 Advisory Group, has attended SAGE meetings, and is on the Royal Society DELVE initiative feeding into SAGE. CS reports grants from BMS, Ono-Pharmaceuticals, and Archer Dx (collaboration in minimal residual disease sequencing technologies), outside the submitted work; personal fees from Bristol Myers Squibb, Roche-Ventana, Ono Pharmaceutical, GlaxoSmithKline, Novartis, Celgene, Illumina, MSD, Sarah Canon Research Institute, Genentech, Bicycle Therapeutics, and Medicixi, outside the submitted work; personal fees and stock options from GRAIL and Achilles Therapeutics, outside the submitted work; and stock options from Epic Biosciences and Apogen Biotechnologies, outside the submitted work. GY directs the Center for Policy Impact in Global Health at Duke University, which has received grant funding from the Bill & Melinda Gates Foundation for policy research that includes policy analysis on COVID-19 control. All other authors declare no competing interests within the submitted work. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2020",

month = oct,

day = "31",

doi = "10.1016/S0140-6736(20)32153-X",

language = "English",

volume = "396",

pages = "e71--e72",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10260",

}

Alwan, NA, Burgess, RA, Ashworth, S, Beale, R, Bhadelia, N, Bogaert, D, Dowd, J, Eckerle, I, Goldman, LR, Greenhalgh, T, Gurdasani, D, Hamdy, A, Hanage, WP, Hodcroft, EB, Hyde, Z, Kellam, P, Kelly-Irving, M, Krammer, F, Lipsitch, M, McNally, A, McKee, M, Nouri, A, Pimenta, D, Priesemann, V, Rutter, H, Silver, J, Sridhar, D, Swanton, C, Walensky, RP, Yamey, G & Ziauddeen, H 2020, 'Scientific consensus on the COVID-19 pandemic: we need to act now', The Lancet, vol. 396, no. 10260, pp. e71-e72. https://doi.org/10.1016/S0140-6736(20)32153-X

TY - JOUR

T1 - Scientific consensus on the COVID-19 pandemic

T2 - we need to act now

AU - Alwan, Nisreen A

AU - Burgess, Rochelle Ann

AU - Ashworth, Simon

AU - Beale, Rupert

AU - Bhadelia, Nahid

AU - Bogaert, Debby

AU - Dowd, Jennifer

AU - Eckerle, Isabella

AU - Goldman, Lynn R

AU - Greenhalgh, Trisha

AU - Gurdasani, Deepti

AU - Hamdy, Adam

AU - Hanage, William P

AU - Hodcroft, Emma B

AU - Hyde, Zoë

AU - Kellam, Paul

AU - Kelly-Irving, Michelle

AU - Krammer, Florian

AU - Lipsitch, Marc

AU - McNally, Alan

AU - McKee, Martin

AU - Nouri, Ali

AU - Pimenta, Dominic

AU - Priesemann, Viola

AU - Rutter, Harry

AU - Silver, Joshua

AU - Sridhar, Devi

AU - Swanton, Charles

AU - Walensky, Rochelle P

AU - Yamey, Gavin

AU - Ziauddeen, Hisham

N1 - Funding Information: This work was not in any way directly or indirectly supported, funded, or sponsored by any organisation or entity. NA has experienced prolonged COVID-19 symptoms. AH advises Ligandal (unpaid advisory role), outside the submitted work. FK is collaborating with Pfizer on animal models of SARS-CoV-2, and with the University of Pennsylvania on mRNA vaccines against SARS-CoV-2. FK has also filed IP regarding serological assays and for SARS-CoV-2, which name him as inventor (pending). PK reports personal fees from Kymab, outside the submitted work; PK also has a patent ‘Monoclonal antibodies to treat and prevent infection by SARS-CoV-2 (Kymab)’ pending and is a scientific advisor to the Serology Working Group (Public Heath England), Testing Advisory Group (Department of Health and Social Care) and the Vaccines Task force (Department for Business, Energy and Industrial Strategy). ML has received honoraria from Bristol-Meyers Squibb and Sanofi Pasteur, outside the submitted work. MM is a member of Independent SAGE and Research Director European Observatory on Health Systems and Policies, which manages the COVID Health Systems Response Monitor. DS sits on the Scottish Government COVID-19 Advisory Group, has attended SAGE meetings, and is on the Royal Society DELVE initiative feeding into SAGE. CS reports grants from BMS, Ono-Pharmaceuticals, and Archer Dx (collaboration in minimal residual disease sequencing technologies), outside the submitted work; personal fees from Bristol Myers Squibb, Roche-Ventana, Ono Pharmaceutical, GlaxoSmithKline, Novartis, Celgene, Illumina, MSD, Sarah Canon Research Institute, Genentech, Bicycle Therapeutics, and Medicixi, outside the submitted work; personal fees and stock options from GRAIL and Achilles Therapeutics, outside the submitted work; and stock options from Epic Biosciences and Apogen Biotechnologies, outside the submitted work. GY directs the Center for Policy Impact in Global Health at Duke University, which has received grant funding from the Bill & Melinda Gates Foundation for policy research that includes policy analysis on COVID-19 control. All other authors declare no competing interests within the submitted work. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2020/10/31

Y1 - 2020/10/31

KW - Betacoronavirus

KW - COVID-19

KW - Communicable Disease Control/methods

KW - Consensus

KW - Coronavirus Infections/prevention & control

KW - Europe

KW - Evidence-Based Medicine

KW - Humans

KW - Immunity, Herd

KW - Pandemics/prevention & control

KW - Pneumonia, Viral/prevention & control

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85094098886&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(20)32153-X

DO - 10.1016/S0140-6736(20)32153-X

M3 - Comment/Letter to the editor

C2 - 33069277

SN - 0140-6736

VL - 396

SP - e71-e72

JO - The Lancet

JF - The Lancet

IS - 10260

ER -

Scientific consensus on the COVID-19 pandemic: we need to act now

Keywords

Access to Document

Other files and links

Cite this